



# Capturing the value of SCOPE to the EU

**Flagship Event**  
**London, 23 November 2016**

**Helen Lee**  
**European Commission, Health and Food Safety Directorate General**

# Outline of the presentation

- Characteristics of Joint Actions
- Pharmacovigilance activities in the EU
- SCOPE Joint Action - impact and sustainability

# Joint Actions

- A specific funding instrument under the EU health programme
- A joint endeavour between the European Commission and the Member States who express interest to be involved

# Joint Actions – Particular characteristics

- Joint Actions have a clear EU added value and are co-financed by Member States
- Involve a greater number of partners than other projects
- Focus on implementation (rather than knowledge production)
- Broad dissemination of deliverables among ALL Member States
- Higher expectation of sustainability

# SCOPE Joint Action

## Objective

- Facilitating collaboration among the Member States for the effective operation of the pharmacovigilance system in the EU

## Main aims

- Support Member States to find solutions for organising and running their pharmacovigilance system in the context of the new pharmacovigilance legislation in the EU
- Support the achievement of a consistent approach to the implementation of the pharmacovigilance legislation across the EU

## Significant EU added value expected

# European Union Pharmacovigilance - a network approach

- Member States
- European Medicines Agency including the Pharmacovigilance Risk Assessment Committee (PRAC)
- European Commission

The European Union



# Advantages of the network approach

- Transparency and early involvement
- Bringing together multiple experts for the benefit of public health
- Collaborative development of (scientific) guidelines taking account of the state-of-the-art
- Facilitating communication with a variety of stakeholders including academia, patients and industry

## Pharmacovigilance activities:

- pro-active risk management
- monitoring of data on the safety of medicines
- acting to protect public health
- communication on risks




# Report on Pharmacovigilance Activities

- Report from the Commission (COM(2016) 498 final) and accompanying staff working document (SWD(2016) 284 final) adopted 8 August 2016
- Includes pharmacovigilance activities of Member States and the European Medicines Agency
- Mainly covering July 2012 – December 2014



# PRAC agenda items




## Member State activities

Total between July 2012 – December 2014 in 28 members of the network:


- Risk management plans: 19 901
- Periodic safety update reports: 11 307
- Post authorisation safety studies: 17
- Post authorisation efficacy studies: 1

# Signal detection – sharing the work




# Risk management plans


Number of RMPs assessed by the PRAC per year



RMPs submitted to NCAs




# PSUR assessments



# PRAC Referrals - collaborative effort


July 2012 – December 2014: 31 pharmacovigilance referrals



# Challenges for MS and PRAC

- Different authorisation procedures
  - central, national, MRP/DCP
- The number of pharmacovigilance procedures and activities
  - RMPs, signals, PSURs, referrals, communication, audits
- Timelines for the assessment procedures
- Identification and promotion of best practices across the network – improving quality, building capacity
- Continuing development of best practice with experience





# Sustainability and impact are interlinked

- *KEY CHALLENGE* - ensuring uptake and use of the deliverables
- The action will impact pharmacovigilance practice **ONLY** if the tools are **ACTUALLY USED** by you
- Embedding deliverables into EU system
- *Potential for added impact by raising awareness on the EU pharmacovigilance system*

# The biggest challenges lie ahead

- Ensuring adequacy and appropriateness of the training material
- Other stakeholder involvement  
e.g. whole network, healthcare professionals, industry, patients
- Ensuring synergy with other activities in the network
- Identification of the ways and the means to sustain the training component

**Goal - effective operation of the PhV system in the EU**

# Thank you for your attention

*European Commission*

*Public Health information:*

[http://ec.europa.eu/health/index\\_en.htm](http://ec.europa.eu/health/index_en.htm)